Adcetris
brentuximab vedotin · CD30Three xenograft models from human HL and ALCL cell lines
Polivy: animal efficacy model or human cells?
polatuzumab vedotin · CD79b
Efficacy evidence
Human DLBCL and B-cell lymphoma xenografts in mice; in vitro Ramos cytotoxicity
“Polatuzumab vedotin demonstrated anti-tumor activity in vitro in CD79b expressing human Burkitt lymphoma (Ramos) cells (IC50 = 0.071 nM) and in vivo in DLBCL and human B-cell lymphoma mouse xenograft models.”
Why that model
Xenograft line co-expressing human and cynomolgus CD79b allowed comparison of clinical and surrogate ADC
“The anti-tumour activity of polatuzumab Ab, polatuzumab vedotin and of the surrogate Ab and ADC was compared in a murine xenograft model with the BJAB Burkitt lymphoma transfectant cell line which expresses comparable amounts of human CD79b and recombinant Cynomolgus CD79b.”
Reviewer's view of the efficacy data
EMA: proof of concept demonstrated in vitro and in DLBCL xenografts, as monotherapy and in combination
“The pharmacological profile of polatuzumab vedotin was demonstrated in in vitro assays and in vivo DLBCL model xenografted in rodents. The proof of concept was successfully demonstrated, an anti tumor efficacy was shown both as monotherapy or combination with rituximab and bendamustine.”
Same question, other ADCs
Besponsa
inotuzumab ozogamicin · CD22Subcutaneous xenograft and systemically disseminated ALL mouse models
Datroway
datopotamab deruxtecan · Trop-2Nude mouse xenografts of human pancreatic cancer, NSCLC and breast cancer
Decnupaz
pivekimab sunirine · CD123Two BPDCN patient-derived xenograft (PDX) models in NSG mice
Elahere
mirvetuximab soravtansine · FRαOvarian cancer xenograft mouse models (single IV dose)
Emrelis
telisotuzumab vedotin · c-Metc-Met-positive NSCLC cell line-derived and patient-derived xenograft mouse models
Enhertu
fam-trastuzumab deruxtecan · HER2HER2-positive breast cancer xenograft mouse models (e.g., KPL-4 in nude mice)
Kadcyla
ado-trastuzumab emtansine · HER2HER2+ xenografts (BT-474 EI, Calu-3) and MMTV-HER2 transgenic tumor model; growth inhibition in all three at 3 to 31 mg/kg
Mylotarg
gemtuzumab ozogamicin · CD33CD33+ HL-60 leukemia xenograft in mice: >80% tumor growth inhibition
Padcev
enfortumab vedotin · Nectin-4Nectin-4-expressing patient-derived bladder cancer xenografts (AG-B1, AG-B8) in mice: >75% tumor growth inhibition
Tivdak
tisotumab vedotin · Tissue factorCervical cancer patient-derived xenograft (PDX) models in mice
Trodelvy
sacituzumab govitecan · Trop-2Mouse xenografts bearing human Trop-2-expressing tumours
Zynlonta
loncastuximab tesirine · CD19CD19-positive human Burkitt lymphoma (Ramos, Daudi) and DLBCL (WSU-DLCL2) xenografts in immunodeficient mice